

Please amend the above-referenced application as follows:

In The Specification:

Please replace the Sequence Listing (1 page) filed on February 13, 2002 with the substitute Sequence Listing (1 page) filed herewith.

Please replace the title at page 1, lines 1 and 2, with the following re-written title:

Complement C3 Precursor Biopolymer Markers ~~Predictive~~  
Indicative Of Alzheimers Disease

Please replace the paragraph beginning at page 37, line 5, with the following rewritten paragraph:

Figure 2 is a trypsin digested spectra graph depicting the ion 1682; SEQ ID NOS:5-7 and SEQ ID NO:1 are shown in the chart as read from top to bottom;

Please replace the paragraph beginning at page 40, line 18, with the following rewritten paragraph:

Preparatory Protocols:

Any of these protocols may be selected from a column flow-through stream, a column elution stream, or a column scrub stream.

Hi Q is a strong anion exchanger made of methyl acrylate co-

polymer with the functional group:  $-N^+(CH_3)_2$ ;

Hi S is a strong cation exchanger made of methyl acrylate co-polymer with the functional group:  $-SO_3^-$ ;

DEAE is a diethylaminoethyl which is a weak cation exchanger made of methyl acrylate co-polymer with the functional group:

$-N^+(C_2H_5)_2$ ;

PS is phenyl sepharose SEPHAROSE;

BS is butyl sepharose SEPHAROSE.

Please replace the paragraph beginning at page 41, line 8, with the following rewritten paragraph:

Note that the supports, i.e. methyl acrylate and sepharose SEPHAROSE are different, but non-limiting examples, as the same functional group on different supports will function, albeit possibly with different effects.

Please replace the paragraph beginning at page 42, line 3, with the following rewritten paragraph:

Butyl sepharose SEPHAROSE column protocol:

- 1) Cast 150  $\mu$ l bed volume column;
- 2) Equilibrate column in 5 bed volumes of 1.7 M  $(NH_4)_2SO_4$  in 50 mM PB pH 7.0 (binding buffer);
- 3) Dissolve 35  $\mu$ l of sera in 465  $\mu$ l of binding buffer

and apply;

- 4) Wash column in 5 bed volumes of binding buffer;
- 5) Elute column in 120  $\mu$ l of 0.4 M  $(\text{NH}_4)_2\text{SO}_4$  in 50 mM PB pH 7.0;
- 6) Elute column in 120  $\mu$ l of 50 mM PB pH 7.0;
- 7) Scrub column with 120  $\mu$ l sequentially with each of 0.1% triton, 1.0% triton and 2% SDS in 62.5 mM Tris pH 6.8.

Please replace the paragraph beginning at page 42, line 18, with the following rewritten paragraph:

Phenyl ~~sepharose~~ SEPHAROSE column protocol:

- 1) Cast 150  $\mu$ l bed volume column;
- 2) Equilibrate column in 5 bed volumes of 1.7 M  $(\text{NH}_4)_2\text{SO}_4$  in 50 mM PB pH 7.0 (binding buffer);
- 3) Dissolve 35  $\mu$ l of sera in 465  $\mu$ l of binding buffer and apply;
- 4) Wash column in 5 bed volumes of binding buffer;
- 5) Elute column in 120  $\mu$ l of 0.2 M  $(\text{NH}_4)_2\text{SO}_4$  in 50 mM PB pH 7.0;
- 6) Elute column in 120  $\mu$ l of 50 mM PB pH 7.0;
- 7) Scrub column with 120  $\mu$ l sequentially with each of 0.1% triton, 1.0% triton and 2% SDS in 62.5 mM Tris pH 6.8.

Please replace the paragraph beginning at page 67, line 2, with the following re-written paragraph:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said the biopolymer, predict disease risk assessment, and develop therapeutic avenues against said the disease.